NOVEL APTAMER AND COMPOSITION FOR IMPROVING COGNITIVE FUNCTION AND ANTI-AGING COMPRISING THE APTAMER AS AN ACTIVE INGREDIENT
A 20mer aptamer with SEQ ID NO: 1, combined with vitamin C, addresses the need for improving cognitive function and anti-aging by enhancing memory and learning abilities and reducing oxidative stress in aging models.
Patent Information
- Application Number
- JP2024528621
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-15
- Filing Date
- 2022-11-14
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2042-11-14
AI Technical Summary
Current health foods and drugs are limited in effectively improving cognitive decline due to natural aging, and there is a need for materials that can enhance cognitive function and delay aging-related cognitive decline.
A 20mer aptamer with the base sequence SEQ ID NO: 1, combined with vitamin C, is used in pharmaceutical and food compositions to improve cognitive function and delay aging effects.
The aptamer and vitamin C combination enhances cognitive function and anti-aging effects by maintaining vitamin C's antioxidant properties, improving memory and learning abilities, and reducing oxidative stress in aging animal models.
Smart Images

Figure 2024543501000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a novel aptamer and a composition for improving cognitive function and anti-aging, which contains the aptamer as an active ingredient. [Background technology]
[0002] According to data from Statistics Korea, in 2017, those aged 65 or over made up 13.8% of the total population in South Korea, indicating that the country has already entered a rapidly aging society, and it is estimated that if aging continues at its current rate, the number of households with people aged 65 or over will approach 47.7% by 2045. The Aging World: 2015 report, published by the US Statistics Bureau in 2016, also predicted that the proportion of South Korea's population aged 65 or over would be 35.9% in 2050 (second only to Japan among the 141 countries surveyed), and reported that South Korea has the fastest aging rate in the world.
[0003] As aging progresses, cognitive function declines, including information processing and learning, perception, reasoning, problem solving, and memory, naturally occur, but in old age, where aging progresses rapidly, cognitive decline is more pronounced than in other age groups. The decline in physical function of the elderly, in combination with the aging phenomenon, has a negative effect on brain function, and the decline in brain function induces serious cognitive decline, making it impossible to maintain normal daily life. Senile cognitive decline ultimately results in individuals being isolated from social activities, resulting in serious impairment of the quality of life in old age.
[0004] Among cognitive functions, memory and learning are known to be formed mainly in the hippocampal formation, which is composed of the hippocampus, dentate gyrus, and subiculum. When certain neurons located in the hippocampal formation are repeatedly stimulated with high-frequency current, the phenomenon of long-term potentiation (LTP) has been reported, in which EPSP (excitatory postsynaptic potential) increases for a long period of time in adjacent neurons connected by synapses. This LTP phenomenon means that the ability to communicate with adjacent neurons connected by synapses is strengthened, and it is accepted as a physiological mechanism of memory / learning and forgetting, along with the opposite phenomenon of LTP, LTD (long-term depression).
[0005] The decline in memory and learning ability is one of the functional changes in the brain that occur with aging, and it is known that as aging progresses, the synaptic density between hippocampal neurons rapidly decreases. As a result, the ability of synaptic plasticity also declines significantly, and as aging progresses, greater stimuli are required to induce LTP and LTD occurs more easily. This decrease in LTP has been reported as the main cause of senile cognitive decline.
[0006] Rapid aging and the increase in life expectancy of the elderly, together with the increasing social interest in quality of life, have amplified the demand for a long and healthy life, and therefore there is an urgent need to develop health foods and drugs that can improve and prevent the decline in cognitive function due to senility. Currently, there are several drugs and health foods for improving senility-related cognitive decline, but they are biased towards specific senility diseases such as Alzheimer's disease, and there is a need to continue to search for active substances that can effectively improve cognitive decline due to natural aging.
[0007] Aptamers, on the other hand, are nucleic acid molecules that have specific binding affinity for molecules through interactions other than the typical Watson-Crick base pairing.
[0008] Aptamers can specifically bind to a selected target and modulate the activity of the target, e.g., through binding, the aptamer can block the ability of the target to function. Generated by an in vitro selection process from a pool of random sequence oligonucleotides, aptamers have been generated across more than 100 proteins, including growth factors, transcription factors, enzymes, immunoglobulins, and receptors. Typical aptamers are 10-15 kDa (30-45 nucleotides) in size, bind their targets with sub-nanomolar affinity, and are distinct from closely related targets (e.g., aptamers typically do not bind to other proteins from the same gene family). A series of structural studies have shown that aptamers can exploit the same types of binding interactions (e.g., hydrogen bonds, electrostatic complementarity, hydrophobic contacts, steric exclusion) that induce affinity and specificity in antibody-antigen complexes.
[0009] Aptamers have many favorable properties for use as therapeutic and diagnostic agents, including high specificity and affinity, biological potency, and excellent pharmacokinetic properties. In addition, aptamers offer specific competitive advantages over antibodies and other protein biologies, such as: 1) Speed and control. Aptamers are generated entirely by in vitro processes, allowing for rapid generation of initial leads, including therapeutic leads. In vitro selection allows for tight control of aptamer specificity and affinity, allowing for generation of leads, including leads against both toxic and non-immunogenic targets.
[0010] 2) Toxicity and immunogenicity. Aptamers as a class show little to no toxicity or immunogenicity. When high doses of aptamers (10 mg / kg daily for 90 days) were administered chronically to rats and woodchucks, no toxicity was observed by clinical, cellular, or biochemical measures. While the efficacy of many monoclonal antibodies is severely limited by the immune response of the antibody itself, it is extremely difficult to induce antibodies against aptamers, since they cannot be generated by T cells via MHC, and the immune response is generally trained not to recognize nucleic acid fragments.
[0011] 3) Administration. Most currently approved antibody therapeutics are administered via intravenous infusion (usually over 2-4 hours), whereas aptamers can be administered via subcutaneous injection (in monkey studies, aptamer bioavailability via subcutaneous administration is >80%).
[0012] This difference is due to the inherently relatively low solubility and therefore the large volume required for most therapeutic MAbs. The excellent solubility (>150 mg / mL) and relatively low molecular weight (aptamers: 10-50 kDa; antibodies: 150 kDa) allows aptamers to be delivered by injection in a volume of 0.5 mL or less for weekly administration. Moreover, the small size of aptamers allows them to penetrate into areas of conformational restriction that antibodies or antibody fragments cannot, which still provides another advantage of aptamer-based therapy or prophylaxis.
[0013] 4) Scalability and cost. Therapeutic aptamers are chemically synthesized and therefore can be easily scaled to the quantities needed to meet production demands. Difficulties in scaling production currently limit some biological uses, and whereas the capital costs of mass-scale protein production plants are prohibitive, a single mass-scale oligonucleotide synthesizer can produce over 100 kg / year and require a relatively modest initial investment. Continued improvements in process development are expected to reduce resource costs to <$100 / g.
[0014] 5) Stability. Therapeutic aptamers are chemically robust: they are inherently adapted to regain activity after exposure to factors such as heat and denaturants, and can be stored for long periods (>1 yr) at room temperature as lyophilized powders. [Prior art documents] [Patent documents]
[0015] [Patent Document 1] Republic of Korea Patent Publication No. 10-2018-0056190 Summary of the Invention [Problem to be solved by the invention]
[0016] The present invention has been devised in response to the above-mentioned needs, and an object of the present invention is to provide an aptamer having an effect of improving cognitive function and having an anti-aging effect.
[0017] Another object of the present invention is to provide a novel composition for improving cognitive function.
[0018] It is yet another object of the present invention to provide a novel anti-aging composition.
[0019] Yet another object of the present invention is to provide a composition for treating and / or ameliorating dementia. [Means for solving the problem]
[0020] To achieve the above object, the present invention provides an aptamer consisting of the base sequence set forth in SEQ ID NO: 1, which retards the oxidation of vitamin C.
[0021] The present invention also provides a pharmaceutical composition for improving cognitive function, comprising the aptamer of the present invention and vitamin C as active ingredients.
[0022] The present invention also provides an anti-aging pharmaceutical composition comprising the aptamer of the present invention and vitamin C as active ingredients.
[0023] The present invention also provides a food composition for improving cognitive function, which contains the aptamer of the present invention and vitamin C as active ingredients.
[0024] The present invention also provides an anti-aging food composition comprising the aptamer of the present invention and vitamin C as active ingredients.
[0025] The present invention also provides a pharmaceutical composition for treating dementia, comprising the aptamer of the present invention and vitamin C as active ingredients.
[0026] The present invention also provides a dementia-alleviating food composition comprising the aptamer of the present invention and vitamin C as active ingredients.
[0027] The present invention will now be described.
[0028] Pharmaceutical Compositions Using Aptamer and / or Vitamin C Complexes When the composition of the present invention is a pharmaceutical composition, it can be used for the indications that the present invention is intended to be applied.For administration of the composition of the present invention, in addition to the above-mentioned active ingredients, it can contain pharma- ceutically acceptable carriers, excipients or diluents.The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
[0029] The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions by a conventional method. In particular, when the pharmaceutical composition is formulated, it can be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such solid preparations may be prepared by mixing at least one or more excipients, such as starch, calcium carbonate, sucrose, lactose, gelatin, and the like, in addition to the active ingredient. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. In addition to liquids for oral administration, such as liquid paraffin, various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, may also be added to prepare the pharmaceutical composition. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, twin 61, cacao butter, laurin butter, glycerogelatin, and the like.
[0030] The suitable dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the patient, the severity of the disease, the form of the drug, and the time, but can be appropriately selected by those skilled in the art. The daily dosage of the composition is preferably 0.001 mg / kg to 500 mg / kg of body weight, and can be administered once or several times a day as necessary.
[0031] Food, beverage and food compositions using aptamer and / or vitamin C complexes The present invention provides a food composition or beverage composition comprising the aptamer of the present invention alone or a complex of the aptamer and vitamin C as an active ingredient.
[0032] In one embodiment of the present invention, the composition preferably further comprises one or more of collagen, elastin, hyaluronic acid, and peptides, but is not limited thereto.
[0033] In one embodiment of the present invention, the food composition is preferably, but not limited to, a confectionery, a candy, a dairy product, a gum, a soy sauce, a bread, or an ice cream.
[0034] Application examples of aptamer-based cosmetics The present invention provides a cosmetic composition comprising an aptamer that reduces the oxidation rate of vitamin C and an additional ingredient.
[0035] The additional ingredient of the present invention may be any raw material used in cosmetics, regardless of the type of extract or active substance. Examples include green tea extract, licorice extract, paper mulberry extract, mulberry bark extract, Scutellaria root extract, kudzu root extract, red ginseng extract, apricot extract, oil extract, orange extract, lemon extract, bamboo extract, guava extract, rosemary extract, Chinese corn extract, lychee extract, ginkgo extract, Xi Shi Yuyong San extract, Zhiyin Dan extract, quince extract, 1000 herb extract, paprika extract, aloe extract, loofah extract, seaweed extract, carrot extract, soybean extract, grapefruit seed extract, grape seed extract, purslane extract, caviar, pomegranate, ginseng extract, peach extract, cnidium extract, Centella asiatica ... -Various extracts are applied, such as mint extract, Chinese laurel extract, Houttuynia cordata extract, peony extract, wood vinegar which is good for anti-inflammatory and antibacterial properties, dandelion extract, calendula extract, Phellodendron amplexicaule extract, betel nut extract, Scutellaria root extract, fennel extract, comfrey extract, chestnut skin extract which helps shrink pores, green tea extract, glycerin which has moisturizing properties, panthenol, hyaluronic acid, ceramide, beta-glucan, arbutin which has whitening effects, vitamin C, whiteness, retinol, astaxanthin, resveratrol, polyphenols, elastin which is good for elasticity, collagen, coenzyme Q10, effectin, EGF, propolis which is an anti-inflammatory and antibacterial agent, allantoin, phytostan, inflammatory acid, antioxidant vitamin E (natural tocopherol), rosemary oil extract, grapefruit seed extract, etc.
[0036] Suitable cosmetic formulations of the present invention may be provided, for example, in the form of a solution, gel, semi-solid or solid cream, toner, lotion, powder, ointment, spray or concealer stick, or may be produced in the form of a foam or in the form of an aerosol composition further comprising a pressurized propellant.
[0037] The cosmetic compositions of the present invention may also contain additional fatty substances, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, moisturizing agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or other adjuvants commonly used in the cosmetic or dermatological fields, and said ingredients may be incorporated in amounts commonly used in the dermatological fields.
[0038] The cosmetic composition of the present invention may be prepared in any formulation commonly used in the art, and specific examples of the formulation include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, essence, nourishing essence, pack, soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, bath aid, and the like. Effect of the Invention
[0039] As can be seen from the present invention, the aptamer of the specific sequence of the present invention (GCCAGTCTCGCGGTGGCGGC) has a superior oxidation retarding effect on vitamin C compared to other previously known aptamers, and the aptamer and / or vitamin C complex of the present invention shows improved cognitive function and anti-aging effects in aging animal models, and by maintaining the reduced state of vitamin C, its antioxidant function can be maintained for a long period of time, and can be used in functional cosmetics of various dosage forms, as well as various health drinks, antioxidant drinks, and antioxidant foods, and can also be applied as a candidate substance required for improving cognitive function and having anti-aging effects. [Brief description of the drawings]
[0040] [Figure 1]This concerns aptamine C332 (left) and aptamine C320 (right). During structural analysis of the 32-mer using mFold, the secondary structure of two stem loop structures was confirmed, and a 20-mer (aptamine C320) was designed that maintains these stem loops. [Diagram 2] 2 is a diagram showing the effect of aptamine C320 in retarding the oxidation of vitamin C through an OPDA assay. In FIG. 2, the sequences are as follows, and the overlapping portions of the 20-mer DNA from C320 to C3a below with the 32-mer DNA (C332) are underlined. C332, GTGGAGGCGGTGGCCAGTCTCGCGGTGGCGGC (SEQ ID NO: 2) C320, GCCAGTCTCGCGGTGGCGGC (SEQ ID NO: 1) C1a, GAGGCGGTGGCCAGTCTCAT (SEQ ID NO: 3) C1b, GCCGGCGGTGGCCGCGGC (SEQ ID NO: 4) C1c, GGAGGCGGTGGCCAGTCTCA (SEQ ID NO: 5) C2c, GAGCTCGCGCCGGAGTTCTC (SEQ ID NO: 6) C3a, GGCGGTGGCCAGTCTCGCGG (SEQ ID NO: 7) In the graph of FIG. 2, the portions marked with 'R' are the C320 aptamer + AA + H2O2 treatment group. [Diagram 3] This figure confirms that aptamine C320 maintains its effect of retarding the oxidation of vitamin C in an environment similar to gastric acid through an OPDA assay. [Figure 4] FIG. 1 shows the change in weight of aged animals during the administration period. [Diagram 5] FIG. 1 shows the measurement of general motility through an open field test. [Figure 6] FIG. 1 shows the evaluation of recognition memory and learning ability through a novel object recognition test (A) and a radial 8-arm maze test (B). [Figure 7]This is a diagram showing the observation of changes in neurons in the hippocampus (CA1, CA3) and motor cortex (MC) in the brain by NeuN staining. [Figure 8] FIG. 1 shows the observation of changes in microglial cells in the hippocampus of the brain using Iba-1 and GFAP staining. [Figure 9] FIG. 1 shows the observation of changes in oxidative stress in the hippocampus and motor cortex regions of the brain by 4HNE staining. [Figure 10-11] These figures show confirmation of changes in DNA damage in the hippocampus and motor cortex of the brain through Lamin A (FIG. 10) and p-H2AX (FIG. 11) staining. [Figure 12] FIG. 1 shows changes in antioxidant capacity in the body through the confirmation of expression of Nrf2 / keap1, SOD1, and GSTO1 / 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0041] The present invention will be described in more detail with reference to the following non-limiting examples. However, the following examples are provided for the purpose of illustrating the present invention, and the scope of the present invention is not to be construed as being limited by the following examples.
[0042] Example 1. Material discovery The aptamer was discovered through SELEX. However, Aptamine C320 was created by shortening the length of the existing vitamin C binding aptamer, 32mer (C332), owned by Nexmos, to 20mer. For comparative experiments, a 20mer aptamer was synthesized and used.
[0043] 1) Structural analysis Sequence-based secondary structure analysis was performed using the mFold program. Through secondary structure analysis of the 32-mer DNA aptamer, it was cut into 20-mer DNA fragments that maintained the secondary structure.
[0044] 2) OPDA assay The aptamer dissolved in the annealing buffer was heated to 95℃, and the temperature was gradually lowered to room temperature to create the secondary structure of the aptamer. It was then mixed with reduced L-ascorbic acid and reacted for about 30 minutes so that the aptamer could bind to L-ascorbic acid. At this time, L-ascorbic acid was mixed at a ratio of 0.1% and aptamer at 0.001%. Hydrogen peroxide was then added to create oxidation conditions, and the oxidation of L-ascorbic acid was measured by adding OPDA (o-phenylenediamine), a fluorescent dye. The amount of fluorescence from DHA-OPDA, which was generated by the reaction of DHA, an oxidized product of L-ascorbic acid, with OPDA, was measured to quantitatively analyze the degree of DHA generation. Under the above conditions, the amount of fluorescence from DHA-OPDA was measured every 2 minutes for a total of 900 minutes.
[0045] The results are shown in Figures 1 and 2.
[0046] Figure 1 shows aptamine C332 (left) and aptamine C320 (right). During structural analysis of the 32-mer using mFold, the secondary structures of two stem-loop structures were confirmed, and a 20-mer (aptamine C320) was designed that maintains these stem-loops.
[0047] FIG. 2 is a diagram showing the effect of aptamine C320 in retarding the oxidation of vitamin C through an OPDA assay. In FIG. 2, the respective sequences are as follows, and the portions of the 20-mer DNA from C320 to C3a that overlap with the 32-mer DNA (C332) are underlined. C332, GTGGAGGCGGTGGCCAGTCTCGCGGTGGCGGC (SEQ ID NO: 2) C320, GCCAGTCTCGCGGTGGCGGC (SEQ ID NO:1) C1a, GAGGCGGTGGCCAGTCTC AT (SEQ ID NO: 3) C1b, GCCGCGGC GGTG GCCGCGGC (SEQ ID NO:4) C1c, G GAGGCGGTGGCCAGTCTC A (SEQ ID NO:5) C2c, GAGCTCGCGCCGGAGTTCTC (SEQ ID NO: 6) C3a, GGCGGTGGCCAGTCTCGCGG (SEQ ID NO:7)
[0048] As shown in Figure 2, OPDA assay was used to confirm whether the existing 32mer (aptamine C332) and aptamine C320 shortened to 20mer can slow down the oxidation of vitamin C, and other aptamers obtained by cleaving aptamine C to 20mer were also tested as comparison groups. As can be seen from Figure 2, aptamine C320 delayed the oxidation of vitamin C the most.
[0049] Therefore, from among the many 20-mer aptamers, aptamine C320 was chosen as a candidate substance for the subsequent experiments.
[0050] Example 2. Confirmation of efficacy maintenance when taken orally To confirm whether the effect of a substance is reduced or eliminated depending on the pH environment in the stomach when the substance is orally ingested, the OPDA assay was used to confirm whether aptamine C320's effect of retarding the oxidation of vitamin C is maintained in a low pH environment similar to that of gastric acid.
[0051] In summary, the aptamer dissolved in the annealing buffer was heated to 95°C, and then the temperature was gradually lowered to room temperature to create the secondary structure of the aptamer. The aptamer was then mixed with reduced L-ascorbic acid and reacted for about 30 minutes so that the aptamer could bind to L-ascorbic acid. Hydrogen peroxide was then added to create oxidation conditions, and the pH was adjusted to between 1.4 and 1.6 using hydrochloric acid. The oxidation of L-ascorbic acid was then measured by adding OPDA (o-phenylenediamine), a fluorescent dye. The amount of fluorescence from DHA-OPDA, which was generated by the reaction of DHA, an oxidized product of L-ascorbic acid, with OPDA, was measured, and the degree of DHA generation was quantitatively analyzed. Under the above conditions, the amount of fluorescence from DHA-OPDA was measured every 2 minutes for a total of 900 minutes.
[0052] The results are shown in Figure 3.
[0053] Figure 3 is a graph confirming the maintenance of Aptamine C320's effect of delaying the oxidation of vitamin C in an environment similar to gastric acid through an OPDA assay, and as can be seen from Figure 3, it was confirmed that Aptamine C320's effect of delaying the oxidation of vitamin C is maintained without significant decrease under acidic conditions compared to normal conditions. Therefore, since the effect of Aptamine C320 is maintained even under strong acidic conditions, it is expected that the effect of Aptamine C320 will not be lost as it passes through the gastrointestinal tract when ingested.
[0054] Example 3. Confirmation of effects in aging experimental animal models Behavioral tests included an open field test, a novel object recognition test, and a radial 8-arm maze test. In relation to changes in neurons in the hippocampus (CA1, CA3) and motor cortex (MC), immunohistochemistry experiments using the NeuN marker were performed. In relation to changes in microglial cells in the hippocampus, immunohistochemistry experiments were performed using Iba-1 and GFAP markers. To observe changes in oxidative stress in the hippocampus and motor cortex, immunohistochemistry was performed using the 4HNE marker. To confirm changes in DNA damage in the hippocampus and motor cortex in the brain, immunohistochemistry using Lamin A as a marker and immunofluorescence experiments using the phospho-histone 2AX (p-H2AX) marker were performed. Changes in antioxidant capacity in the body were confirmed by immunofluorescence and western blot using Nrf2, Keap1, SOD1, and GSTO1 / 2 as antioxidant markers.
[0055] In summary: 1)Animals In order to standardize the special physical condition of the animals in old age, imported animals from Charles River Japan were introduced. 70-week-old male B6J animals were imported through Orient Bio. After customs clearance, the imported animals were to be delivered to the laboratory using a vibration-free train, and were separated into two animals per cage and housed in a thermo-hygrostat that maintained the set environment (23±2°C, 50±1%, 12-hour light / dark cycles). Water and food were available ad libitum.
[0056] 2) Testing After allowing B6J mice to adapt to the experimental environment for one week, they were randomly assigned to groups of 10 mice each. After that, all mice in all groups were orally administered Aptamine C320 / vitamin C complex, Aptamine C320 alone, or vitamin C alone every day for 8 weeks according to the intervention of each group. After applying the experimental intervention for two weeks, cognitive function was evaluated through behavioral experiments. The behavioral experiments included a novel object recognition test and an 8-arm radical maze test to confirm cognitive function, and an open field test to confirm motor function. The day after the behavioral experiments, the mice were anesthetized by inhalation using ethyl ether, dislocated cervically, and sacrificed painlessly to obtain tissues.
[0057] 3)Histological analysis To confirm histological differences, tissues were collected after sacrificing the animals. After obtaining brain tissue, it was fixed in 10% formalin solution for 1 hour. For the formalin-fixed tissue, a paraffin block was prepared and cut to a thickness of 5 μm from the outside to prepare sections. After removing the paraffin with xylene and washing with alcohol and distilled water, markers of nerve (NeuN), inflammation (Iba-1, GFAP), oxidation (4-HNE), antioxidant (Nrf2 / Keap1), and senescence (Lamin A, p-H2AX) were stained as primary antibodies. After the reaction of the secondary antibody, data were collected by observation under a microscope.
[0058] 4) Western blotting Brain tissue was crushed in a lysis buffer containing a protein degradation inhibitor (Trizma base, NaCl, 10% NP40, 10% Na-dedoxycholate, 100mM EDTA, and 10% SDS) to make a homogenate. Then, it was centrifuged at 13,000 rpm for 30 minutes while maintaining 4℃. The supernatant was taken to obtain proteins, and the proteins were separated by electrophoresis in a uniform amount on an SDS PAGE gel. The proteins were then transferred from the gel to a PVDF membrane, blocked with 5% skim milk for 1 hour, and reacted with a primary antibody at 4℃ overnight. The primary antibodies reacted with SOD-1 and GSTO1 / 2 to confirm the antioxidant effect. Each was reacted with an HRP-conjugated secondary antibody at room temperature for 2 hours, reacted with an ECL (enhanced chemiluminescence) solution, and developed on a film. The amount of the expressed target protein was compared with that of β-actin, which was a positive control, and the expression amount was measured using the Image J program.
[0059] 5) Statistical analysis To evaluate the therapeutic effects of Aptamine C320 and Vitamin C complex, the SPSS 25.0 program was used for analysis. If the collected data was normal, it was analyzed through one-way ANOVA, otherwise through the non-parametric Kruskal Wallis test. If differences between groups occurred, Tukey test was performed as a post-hoc test. The significance of statistical differences was limited to p-values less than 0.05. All data values were expressed as mean ± standard error (SEM). (*p<0.05, compared with the Young group. #p<0.05, compared with the Aging group)
[0060] In the present embodiment, the drug dosage is: Vitamin C 200mg / kg Aptamine C320 4mg / kg Aptamine C320 + Vitamin C 4mg / 200mg / kg The results of the above examples are described below.
[0061] Figure 4 shows the change in weight of aged animals during the administration period, and the weight of the aged animals was measured once a week during the 8-week administration period. As can be seen from Figure 4, there was no change in the weight of the animals due to the administration of the substance, and there was no significant difference between the groups.
[0062] Figure 5 shows the general motility measurement through the open field test. General and spontaneous motility was analyzed through the open field test. As can be seen from Figure 5, there was no statistically significant difference between the groups in the way the animals moved in the whole space and the center of the space. Therefore, it is considered that there is no significant difference in spontaneous motility.
[0063] FIG. 6 shows the evaluation of cognitive memory and learning ability through a novel object recognition test and a radial 8-arm maze test. [A] Novel object recognition test The novel object recognition test is a cognitive memory evaluation model that uses the characteristic of mice to show curiosity about novel things. As can be seen from Figure 6A, the aging-vehicle group showed a decline in cognitive function compared to the young group, while the aging-AptaminC320+VitaminC group showed more interest in novel objects and improved cognitive memory compared to the aging-vehicle group.
[0064] [B] 8-arm radial maze test The 8-arm radial maze test is a method for measuring spatial learning ability. In a maze consisting of 8 arms, re-entering a previously visited arm is counted as an error, and the number of correct choices is counted until the first error occurs. As can be seen from Figure 6B, in the 8-arm radial maze, the aging-vehicle group made fewer correct choices and more errors compared to the young group. In comparison, the aging-AptaminC320+VitaminC group made more correct choices and fewer errors.
[0065] Therefore, it is believed that spatial learning and memory function were improved by ingestion of the AptaminC320+VitaminC complex.
[0066] FIG. 7 shows the observation of changes in neurons in the hippocampus (CA1, CA3) and motor cortex (MC) in the brain by NeuN staining. The CA1, CA3 and motor cortex regions of the hippocampus are involved in spatial and working memory, and are important in memory search and formation. As can be seen from FIG. 7, NeuN is a marker for neurons, and the number of NeuN-positive cells was significantly reduced in the aging group, but the number of NeuN-positive cells increased in the group that took AptaminC320+VitaminC. Therefore, it was confirmed that the intake of the combination of AptaminC320+VitaminC suppressed the death of neurons due to aging.
[0067] Figure 8 shows the observation of changes in microglial cells in the hippocampus of the brain by Iba-1 and GFAP staining, and microglia and astrocytes increase when the central nervous system is damaged and stressed. As can be seen from Figure 8, in the hippocampus, Iba-1, an inflammation marker of microglia cells, and GFAP, an inflammation marker of astrocytes, increased with aging, and were statistically significantly reduced by taking the combination of AptaminC320+VitaminC.
[0068] Figure 9 shows the change in oxidative stress in the hippocampus and motor cortex of the brain observed by 4HNE staining. 4HNE is an oxidative stress biomarker produced by lipid peroxidation. As can be seen from Figure 9, an increase in 4HNE-positive cells was confirmed in the hippocampus CA1, CA3 and motor cortex regions, indicating an increase in oxidative stress in senescent cells. The intake of the AptaminC320+VitaminC combination drug statistically significantly reduced the accumulation of 4HNE in senescent cells.
[0069] 10 and 11 are diagrams showing changes in DNA damage in the hippocampus and motor cortex of the brain confirmed through Lamin A (FIG. 10) and p-H2AX (FIG. 11) staining. [Figure 10] Lamin A is an indicator of aging-related nuclear damage, which accumulates during natural aging and is activated when cells are exposed to oxidative stress. We confirmed that expression of Lamin A in the hippocampus CA1, CA3, and motor cortex of aged animals was increased compared to young animals. As can be seen from Figure 10, the group administered the combination of Aptamin C320 + Vitamin C showed a statistically significant decrease in Lamin A positive cells compared to the aged group.
[0070] [Figure 11] p-H2AX is closely related to the repair of damaged DNA. The expression of p-H2AX was statistically significantly decreased in the hippocampal CA1, CA3 and motor cortex regions of aged mice compared to young mice. However, the administration of the combination of AptainC320+VitaminC resulted in a statistically significant increase in the expression of p-H2AX.
[0071] FIG. 12 shows changes in antioxidant capacity in the body through the confirmation of the expression of Nrf2 / keap1, SOD1, and GSTO1 / 2. Nrf2 is a transcription factor that regulates the expression of various antioxidant genes and is involved in the regulation of cell defense and antioxidant mechanisms.
[0072] As can be seen from Figure 12, in the aging group, Nrf2 was mainly located in the cytoplasm, and its expression was decreased compared to the young group. In contrast, administration of the Aptamin C320 + Vitamin C combination increased the expression of Nrf2, which had decreased due to aging. In addition, it was confirmed that SOD-1 and GSTO1 / 2, antioxidant enzymes regulated by Nrf2, were increased compared to the aging group.
Claims
1. An aptamer consisting of the base sequence set forth in SEQ ID NO: 1 that slows down the oxidation of vitamin C.
2. A pharmaceutical composition for improving cognitive function, comprising the aptamer according to claim 1 and vitamin C as active ingredients.
3. An anti-aging pharmaceutical composition comprising the aptamer according to claim 1 and vitamin C as active ingredients.
4. A food composition for improving cognitive function, comprising the aptamer according to claim 1 and vitamin C as active ingredients.
5. An anti-aging food composition comprising the aptamer according to claim 1 and vitamin C as active ingredients.
6. A pharmaceutical composition for treating dementia, comprising the aptamer according to claim 1 and vitamin C as active ingredients.
7. A dementia-alleviating food composition comprising the aptamer of claim 1 and vitamin C as active ingredients.
Citation Information
Patent Citations
An Aptamer-based vitamin and antioxidant beverages and foods, and a producing method thereof
KR1020180056190A
KR20210060638A
